Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Mucositis Oral, Head and Neck Cancer
Interventions: MucoLox, Sodium Bicarbonate; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Prostate Cancer
Interventions: HE3235; Drug
Lead sponsor: Harbor Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Scottsdale, Arizona • Encinitas, California • Roseville, California + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Glimepiride, Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 16
States / cities: Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more

Conditions: Palmoplantar Pustulosis
Interventions: Bimekizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more

Conditions: Graft Versus Host Disease, Stem Cell Transplantation
Interventions: voriconazole; Drug
Lead sponsor: Phillip Brian Smith; Other
Eligibility: Up to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ANXIETY
Interventions: Alprazolam orally disintegrating tablets; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Timeline: 2004
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Oral Leukoplakia
Interventions: Lozenge Intake; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Periodontal Bone Loss
Interventions: Enamel Matrix Proteins Derivative, Saline; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Thrombocytopenia Related to Chronic Liver Disease
Interventions: Avatrombopag, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: TERN-501, TERN-101, Placebo; Drug · Other
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 35
States / cities: Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more

Conditions: Head and Neck Cancer
Interventions: Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 10
States / cities: New Haven, Connecticut • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Healthy
Interventions: Tofacitinib tablet, Tofacitinib Oral Solution; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lip and Oral Cavity Cancer, Head and Neck Cancer, Oropharyngeal Cancer
Interventions: cisplatin, fluorouracil, ONYX-015; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Neladenoson bialanate (BAY1067197), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Naples, Florida • Detroit, Michigan • Jackson, Mississippi + 6 more

Conditions: Gonorrhea
Interventions: zoliflodacin, ceftriaxone, azithromycin; Drug
Lead sponsor: Global Antibiotics Research and Development Partnership; Other
Eligibility: 12 Years and older
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Peanut Allergy
Interventions: walnut powder; Drug
Lead sponsor: Jonathan Spergel; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Interventions: Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire, Video-Strobe Procedure, MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning, Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning, Intensity Modulated Radiotherapy (IMRT); Procedure · Behavioral · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastroesophageal Reflux Disease
Interventions: E3710; Drug
Lead sponsor: Eisai Co., Ltd.; Industry
Eligibility: 20 Years to 40 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Non-small Cell Lung Cancer
Interventions: NRX194204; Drug
Lead sponsor: NuRx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Fountain Valley, California • La Jolla, California • Los Angeles, California + 3 more

Conditions: Aplastic Anemia
Interventions: Eltrombopag, hATG, CsA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more

Conditions: Head And Neck Cancer, Oropharynx Cancer
Interventions: Visual Examination, OraTest; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 45 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

A Phase I/II Study of HE3235 in Patients With Prostate Cancer

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Zoliflodacin in Uncomplicated Gonorrhoea

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Walnut Oral Immunotherapy for Tree Nut Allergy

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

OraTest in Combination With Visual Examination and Visual Examination Alone

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus